US Stock MarketDetailed Quotes
BDRX Biodexa Pharmaceuticals
- 5.6200
- +0.6900+14.00%
Close Nov 29 13:00 ET
- 5.6900
- +0.0700+1.25%
Post 17:01 ET
3.26MMarket Cap-2P/E (TTM)
5.6200High4.9401Low66.40KVolume5.0000Open4.9300Pre Close359.18KTurnover23.62%Turnover RatioLossP/E (Static)580.84KShares103.000052wk High0.29P/B1.58MFloat Cap3.500052wk Low--Dividend TTM281.14KShs Float14680000.0000Historical High--Div YieldTTM13.79%Amplitude3.5000Historical Low5.4090Avg Price1Lot Size
Biodexa Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | (FY)Dec 31, 2017 | (FY)Dec 31, 2016 | (FY)Dec 31, 2015 | (FY)Dec 31, 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 3.15%-6.83M | -17.31%-7.05M | 35.40%-6.01M | -9.3M | ||||||
| Net income from continuing operations | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | 6.44%-15.03M | 20.33%-16.06M | -99.64%-20.16M | -14.48%-10.1M | -116.01%-8.82M |
| Operating gains losses | -6.59%-485K | 53.48%-455K | -275.27%-978K | --558K | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -17.49%283K | -14.89%343K | -66.89%403K | --1.22M | ---- | ---- | ---- | ---- | ---- | ---- |
| Deferred tax | 51.20%-406K | -28.79%-832K | 49.57%-646K | 28.24%-1.28M | 12.16%-1.79M | -60.63%-2.03M | 86.19%-1.27M | -708.47%-9.16M | -11.30%-1.13M | -27.41%-1.02M |
| Other non cash items | -275.00%-42K | -45.45%24K | 33.33%44K | -94.02%33K | -5.64%552K | 334.94%585K | 80.30%-249K | 31.71%-1.26M | -1,309.80%-1.85M | -60.16%153K |
| Change In working capital | -109.42%-49K | 184.28%520K | 60.40%-617K | -186.65%-1.56M | 223.74%1.8M | -1.11%-1.45M | -1,087.60%-1.44M | 86.42%-121K | -172.62%-891K | 258.94%1.23M |
| -Change in receivables | 5,114.29%365K | 101.44%7K | -198.78%-487K | -32.00%493K | -29.61%725K | 206.40%1.03M | -300.00%-968K | 84.29%-242K | -302.37%-1.54M | 272.17%761K |
| -Change in inventory | ---- | ---- | ---- | ---- | ---- | 271.78%347K | 14.77%-202K | -282.26%-237K | ---62K | --0 |
| -Change in payables and accrued expense | -158.15%-207K | 373.85%356K | 93.51%-130K | ---2M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Change in other working capital | -231.85%-207K | --157K | ---- | ---47K | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 3.15%-6.83M | -17.31%-7.05M | 35.40%-6.01M | -43.33%-9.3M | 51.75%-6.49M | -3.84%-13.45M | 1.02%-12.95M | -5.35%-13.09M | -127.70%-12.42M | -22.97%-5.46M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -20.45%-265K | 20.86%-220K | -110.80%-278K | 2.57M | ||||||
| Net PPE purchase and sale | 47.62%-22K | 84.89%-42K | -321.21%-278K | 78.71%-66K | -41.55%-310K | 69.02%-219K | 47.51%-707K | -46.10%-1.35M | 10.49%-922K | -2,091.49%-1.03M |
| Net intangibles purchase and sale | ---237K | --0 | --0 | ---- | ---9K | --0 | -3,994.74%-778K | -533.33%-19K | ---3K | --0 |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---947K | ---- | ---- | --0 | -674.78%-661K | --115K |
| Net other investing changes | 61.84%-79K | ---207K | ---- | 203.53%2.64M | -127.53%-2.55M | --9.26M | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -20.45%-265K | 20.86%-220K | -110.80%-278K | 167.61%2.57M | -142.10%-3.81M | 715.10%9.04M | -22.30%-1.47M | 21.59%-1.2M | -69.02%-1.53M | -1,714.00%-907K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 21,657.45%10.23M | -99.47%47K | 185.51%8.81M | 3.08M | ||||||
| Net issuance payments of debt | -5.62%-188K | 17.21%-178K | 96.52%-215K | -260.20%-6.18M | 166.29%3.86M | -224.25%-5.82M | 2,855.88%4.69M | -3.03%-170K | -130.33%-165K | -48.24%544K |
| Net common stock issuance | 4,190.95%10.43M | -97.31%243K | -7.26%9.04M | -30.95%9.74M | --14.11M | --0 | --5.73M | ---- | ---- | ---- |
| Cash dividends paid | --0 | --0 | --0 | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | -120.11%-229K | --1.14M | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 21,657.45%10.23M | -99.47%47K | 185.51%8.81M | -83.54%3.08M | 389.45%18.73M | -162.98%-6.47M | -32.63%10.28M | 7,065.75%15.26M | -100.64%-219K | 408.90%34.3M |
| Net cash flow | ||||||||||
| Beginning cash position | -71.80%2.84M | 33.28%10.06M | -30.95%7.55M | 366.41%10.93M | -82.26%2.34M | -25.01%13.2M | 8.86%17.61M | -46.66%16.18M | 1,170.42%30.33M | 1,694.74%2.39M |
| Current changes in cash | 143.42%3.14M | -386.66%-7.22M | 169.15%2.52M | -143.18%-3.64M | 177.55%8.44M | -162.42%-10.88M | -528.75%-4.15M | 106.82%967K | -150.73%-14.17M | 1,139.49%27.94M |
| Effect of exchange rate changes | --0 | --0 | -103.07%-8K | 76.35%261K | 678.95%148K | 107.36%19K | -155.36%-258K | 1,926.09%466K | --23K | --0 |
| End cash Position | 110.54%5.97M | -71.80%2.84M | 33.28%10.06M | -30.95%7.55M | 366.41%10.93M | -82.26%2.34M | -25.01%13.2M | 8.86%17.61M | -46.66%16.18M | 1,170.42%30.33M |
| Free cash flow | 0.30%-7.09M | -12.36%-7.11M | 33.46%-6.33M | -39.69%-9.51M | 50.28%-6.81M | 5.15%-13.69M | 0.10%-14.44M | -8.29%-14.45M | -105.80%-13.35M | -44.56%-6.49M |
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
